abatacept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: T-lymphocyte activation antigen CD80.
- Target
- T-lymphocyte activation antigen CD80
- Mechanism
- T-lymphocyte activation antigen CD80 inhibitor
pharma · Rheumatoid Arthritis
Dr. Reddy's Laboratories
Dr Reddy''s Laboratories (Australia) Pty Ltd
Dr. Reddy's Laboratories drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Princeton, USA HQ
6 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Princeton, USA
- Employees
- 6
- Programs
- 1
- Drugs
- 7
- Patents
- 0
Dr. Reddy's Laboratories pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Dr. Reddy's Laboratories drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Dr. Reddy's Laboratories in public FDA and regional records.
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Dr. Reddy's Laboratories in public FDA and regional records.
-
Development asset linked to Dr. Reddy's Laboratories in public FDA and regional records.
-
toripalimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Dr. Reddy's Laboratories's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
trientine
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Dr. Reddy's Laboratories's portfolio.